Critically Dysregulated Signaling Pathways and Clinical Utility of The pathway Biomarkers in Lymphoid Malignancies

Overview

Journal Chronic Dis Transl Med

Publisher Wiley

Date 2018 May 15

PMID 29756121

Citations 11

Authors

Rui-Fang Sun

Qian-Qian Yu

Ken H Young

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence confirmed that many dysregulated signaling pathways and aberrant genetic alterations contribute to the oncogenesis and heterogeneity of lymphoid malignancies. Therapeutically targeting dysregulating signaling pathways and their hidden oncogenic biomarkers are becoming available, but did not show desired therapeutic effect in current clinical practice. It is meaningful to further understand the underlying mechanisms of the dysregulated signaling pathways and to address the potential utility of pathway-related biomarkers. To precisely identify the dysregulation of signaling pathways and the "driver" oncogenic biomarkers, as well as to develop reliable and reproducible risk-stratification based on biomarkers will be challenging. Nevertheless, pathway-based targeted therapy will raise the hope to improve the outcomes of the patients with lymphoid malignancies, especially with aggressive types, and the efficient utility of pathway-related biomarkers in diagnosis, prognosis, prediction of lymphoid malignancies may also be able to power precision medicine.

Citing Articles

Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.

Alfaifi A, Bahashwan S, Alsaadi M, Ageel A, Ahmed H, Fatima K Adv Hematol. 2024; 2024:5948170.

PMID: 39563886 PMC: 11576080. DOI: 10.1155/2024/5948170.

Non‑Hodgkin's lymphomas of the lacrimal sac: Current insights and future directions (Review).

Athanasopoulos M, Nomikos G, Samara P, Mastronikolis S, Tsilivigkos C, Mastronikolis N Med Int (Lond). 2024; 4(4):43.

PMID: 38912417 PMC: 11190882. DOI: 10.3892/mi.2024.167.

Extranodal lymphoma: pathogenesis, diagnosis and treatment.

Yang H, Xun Y, Ke C, Tateishi K, You H Mol Biomed. 2023; 4(1):29.

PMID: 37718386 PMC: 10505605. DOI: 10.1186/s43556-023-00141-3.

Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma.

Alfaifi A, Refai M, Alsaadi M, Bahashwan S, Malhan H, Al-Kahiry W Diagnostics (Basel). 2023; 13(5).

PMID: 36900005 PMC: 10000528. DOI: 10.3390/diagnostics13050861.

Hodgkin Lymphoma Cell Lines and Tissues Express mGluR5: A Potential Link to Ophelia Syndrome and Paraneoplastic Neurological Disease.

Schnell S, Knierim E, Bittigau P, Kreye J, Hauptmann K, Hundsdoerfer P Cells. 2023; 12(4).

PMID: 36831273 PMC: 9953995. DOI: 10.3390/cells12040606.

References

Chipuk J, Maurer U, Green D, Schuler M . Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell. 2003; 4(5):371-81. DOI: 10.1016/s1535-6108(03)00272-1. View

Loiarro M, Ruggiero V, Sette C . Targeting the Toll-like receptor/interleukin 1 receptor pathway in human diseases: rational design of MyD88 inhibitors. Clin Lymphoma Myeloma Leuk. 2013; 13(2):222-6. DOI: 10.1016/j.clml.2013.02.003. View

Davis R, Brown K, Siebenlist U, Staudt L . Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12):1861-74. PMC: 2193582. DOI: 10.1084/jem.194.12.1861. View

Sharma P, Allison J . Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161(2):205-14. PMC: 5905674. DOI: 10.1016/j.cell.2015.03.030. View

Younes A . Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. 2010; 8(2):85-96. PMC: 3192435. DOI: 10.1038/nrclinonc.2010.189. View

Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A . Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015; 171(4):463-70. PMC: 5278973. DOI: 10.1111/bjh.13603. View

Munoz-Pinedo C . Signaling pathways that regulate life and cell death: evolution of apoptosis in the context of self-defense. Adv Exp Med Biol. 2012; 738:124-43. DOI: 10.1007/978-1-4614-1680-7_8. View

Green M, Monti S, Rodig S, Juszczynski P, Currie T, ODonnell E . Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116(17):3268-77. PMC: 2995356. DOI: 10.1182/blood-2010-05-282780. View

Brusa D, Serra S, Coscia M, Rossi D, DArena G, Laurenti L . The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013; 98(6):953-63. PMC: 3669453. DOI: 10.3324/haematol.2012.077537. View

10.

Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim K . Oncogenically active MYD88 mutations in human lymphoma. Nature. 2010; 470(7332):115-9. PMC: 5024568. DOI: 10.1038/nature09671. View

11.

Zarnegar B, Wang Y, Mahoney D, Dempsey P, Cheung H, He J . Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol. 2008; 9(12):1371-8. PMC: 2676931. DOI: 10.1038/ni.1676. View

12.

Shaffer 3rd A, Young R, Staudt L . Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012; 30:565-610. PMC: 7478144. DOI: 10.1146/annurev-immunol-020711-075027. View

13.

Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B . Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-16. PMC: 4513941. DOI: 10.1056/NEJMoa1306220. View

14.

Lenz G, Davis R, Ngo V, Lam L, George T, Wright G . Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008; 319(5870):1676-9. DOI: 10.1126/science.1153629. View

15.

Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos C . Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009; 15(18):5724-32. DOI: 10.1158/1078-0432.CCR-08-3215. View

16.

Goy A, Berger M, Ford P, Feldman T, Mato A, Bejot C . Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma. Leuk Lymphoma. 2014; 55(12):2932-4. DOI: 10.3109/10428194.2014.900760. View

17.

Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View

18.

Gilbert J . Idelalisib: targeting PI3Kδ in B-cell malignancies. Lancet Oncol. 2014; 15(3):e108. DOI: 10.1016/s1470-2045(14)70052-x. View

19.

Hay N, Sonenberg N . Upstream and downstream of mTOR. Genes Dev. 2004; 18(16):1926-45. DOI: 10.1101/gad.1212704. View

20.

Milhollen M, Traore T, Adams-Duffy J, Thomas M, Berger A, Dang L . MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood. 2010; 116(9):1515-23. DOI: 10.1182/blood-2010-03-272567. View